For persons receiving chemotherapy of high emetic risk , there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics .
In all patients receiving cisplatin and all other agents of high emetic risk , the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis .
The Up date Committee no longer recommends the combination of a 5-HT3 serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk .
PURPOSE To up date the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology .
Anticipatory nausea and vomiting: prevalence and predictors in chemotherapy patients.
One hundred and seventy-five patients selected at r and om were prospect ively studied . All patients were assessed at least after the first cycle of treatment by a self-report question naire which covered the occurrence of nausea and vomiting 24 before chemotherapy , as well as information regarding 22 clinical parameters . Forty-six ( 26 % ) patients developed anticipatory nausea . ' Intolerable ' posttreatment vomiting and age under 45 were statistically significant parameters ( p less than 0.05 ) in the multivariate analysis . Twenty-one ( 12 % ) of the 175 patients experienced anticipatory vomiting . Three variables , age under 45 , ' intolerable ' posttreatment vomiting and more than three cycles of treatment were found to be significant ( p less than 0.05 ) . The relative risk of developing anticipatory nausea and vomiting according to combination of significant clinical predictors in the multivariate analysis is proposed . Therefore recognition of these clinical predictors may serve as a marker for patients with high risk of presenting anticipatory nausea and vomiting , who may benefit from prophylactic behavioral approaches
For persons receiving chemotherapy of high emetic risk , there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics .
In all patients receiving cisplatin and all other agents of high emetic risk , the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis .
The Up date Committee no longer recommends the combination of a 5-HT3 serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk .
PURPOSE To up date the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology .